Cellular drug resistance of 5 specific genetic subgroups in childhood AML
| Drug . | Abnormalities 5/7 . | 11q23 with t(9;11) . | 11q23; non-t(9;11) . | t(15;17) . | Trisomy 8 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | |
| Ara-C | 8 | 1.56 (0.56-1.96) | 9 | 0.16 (0.11-0.25) | 8 | 0.57 (0.42-0.78) | 3 | 1.60 (1.18-1.74)4-153 | 4 | 0.28 (0.20-0.88) |
| DNR | 6 | 0.29 (0.22-0.63) | 8 | 0.08 (0.03-0.11) | 8 | 0.13 (0.10-0.41) | 3 | 0.34 (0.11-1.32)4-153 | 2 | 0.05 (0.04-0.05)4-153 |
| Dox | 4 | 0.42 (0.37-0.70) | 6 | 0.11 (0.08-0.18) | 6 | 0.68 (0.43-0.97) | 3 | 0.48 (0.39-1.71)4-153 | 3 | 0.43 (0.11-0.46)4-153 |
| Ida | 6 | 0.16 (0.04-0.27) | 6 | 0.06 (0.01-0.10) | 6 | 0.10 (0.05-0.26) | 2 | 0.62 (0.20-1.04)4-153 | 3 | 0.05 (0.03-0.10)4-153 |
| VP16 | 7 | 18.42 (8.57-27.09) | 9 | 0.68 (0.63-1.60) | 8 | 4.72 (2.35-23.98) | 3 | 12.50 (3.59-33.15)4-153 | 4 | 1.83 (1.28-4.01) |
| 6-TG | 8 | 5.89 (3.92-13.76) | 9 | 4.88 (3.13-8.80) | 8 | 9.58 (6.88-23.50) | 3 | 17.61 (4.50-43.33)4-153 | 4 | 6.10 (3.58-6.14) |
| Mitox | 8 | 0.08 (0.03-0.27) | 8 | 0.01 (0.00-0.03) | 5 | 0.05 (0.01-0.61) | 2 | 0.57 (0.04-1.10)4-153 | 2 | 0.09 (0.04-0.14)4-153 |
| Amsa | 7 | 1.08 (0.18-1.20) | 8 | 0.10 (0.05-0.29) | 7 | 0.21 (0.15-1.13) | 3 | 0.14 (0.13-2.07)4-153 | 3 | 0.07 (0.06-0.31)4-153 |
| CdA | 5 | 0.025 (0.020-0.036) | 8 | 0.002 (0.002-0.004) | 6 | 0.008 (0.001-0.026) | 2 | 7.15 (0.02-14.29)4-153 | 1 | 0.028 |
| Bus | 6 | 42.4 (28.6-67.7) | 8 | 9.6 (7.1-35.8) | 6 | 51.5 (34.9-59.4) | 3 | 49.2 (48.3-72.6)4-153 | 3 | 67.6 (55.6-180)4-153 |
| Ifos | 6 | 12.17 (11.29-14.10) | 9 | 5.97 (4.92-12.04) | 7 | 13.85 (13.82-14.50) | 2 | 17.21 (16.1-18.3)4-153 | 1 | 22.62 |
| Pred | 7 | >250 (>250->250) | 9 | >250 (>250->250) | 8 | >250 (>250->250) | 3 | >250 (>250->250)4-153 | 4 | >250 (194->250) |
| VCR | 7 | 12.50 (1.95-28.52) | 7 | 0.60 (0.24-1.18) | 7 | 18.36 (1.33-38.00) | 3 | 0.50 (0.14-9.15)4-153 | 4 | 20.19 (1.82-41.60) |
| ASP‡ | 6 | 1.45 (0.49-1.77) | 8 | 0.14 (0.01-0.59) | 5 | 1.36 (0.03-10.10) | 2 | >10.0 (>10.0->10.0)4-153 | 2 | 0.66 (0.51-0.80)4-153 |
| Drug . | Abnormalities 5/7 . | 11q23 with t(9;11) . | 11q23; non-t(9;11) . | t(15;17) . | Trisomy 8 . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | n . | Median (P25-P75) . | |
| Ara-C | 8 | 1.56 (0.56-1.96) | 9 | 0.16 (0.11-0.25) | 8 | 0.57 (0.42-0.78) | 3 | 1.60 (1.18-1.74)4-153 | 4 | 0.28 (0.20-0.88) |
| DNR | 6 | 0.29 (0.22-0.63) | 8 | 0.08 (0.03-0.11) | 8 | 0.13 (0.10-0.41) | 3 | 0.34 (0.11-1.32)4-153 | 2 | 0.05 (0.04-0.05)4-153 |
| Dox | 4 | 0.42 (0.37-0.70) | 6 | 0.11 (0.08-0.18) | 6 | 0.68 (0.43-0.97) | 3 | 0.48 (0.39-1.71)4-153 | 3 | 0.43 (0.11-0.46)4-153 |
| Ida | 6 | 0.16 (0.04-0.27) | 6 | 0.06 (0.01-0.10) | 6 | 0.10 (0.05-0.26) | 2 | 0.62 (0.20-1.04)4-153 | 3 | 0.05 (0.03-0.10)4-153 |
| VP16 | 7 | 18.42 (8.57-27.09) | 9 | 0.68 (0.63-1.60) | 8 | 4.72 (2.35-23.98) | 3 | 12.50 (3.59-33.15)4-153 | 4 | 1.83 (1.28-4.01) |
| 6-TG | 8 | 5.89 (3.92-13.76) | 9 | 4.88 (3.13-8.80) | 8 | 9.58 (6.88-23.50) | 3 | 17.61 (4.50-43.33)4-153 | 4 | 6.10 (3.58-6.14) |
| Mitox | 8 | 0.08 (0.03-0.27) | 8 | 0.01 (0.00-0.03) | 5 | 0.05 (0.01-0.61) | 2 | 0.57 (0.04-1.10)4-153 | 2 | 0.09 (0.04-0.14)4-153 |
| Amsa | 7 | 1.08 (0.18-1.20) | 8 | 0.10 (0.05-0.29) | 7 | 0.21 (0.15-1.13) | 3 | 0.14 (0.13-2.07)4-153 | 3 | 0.07 (0.06-0.31)4-153 |
| CdA | 5 | 0.025 (0.020-0.036) | 8 | 0.002 (0.002-0.004) | 6 | 0.008 (0.001-0.026) | 2 | 7.15 (0.02-14.29)4-153 | 1 | 0.028 |
| Bus | 6 | 42.4 (28.6-67.7) | 8 | 9.6 (7.1-35.8) | 6 | 51.5 (34.9-59.4) | 3 | 49.2 (48.3-72.6)4-153 | 3 | 67.6 (55.6-180)4-153 |
| Ifos | 6 | 12.17 (11.29-14.10) | 9 | 5.97 (4.92-12.04) | 7 | 13.85 (13.82-14.50) | 2 | 17.21 (16.1-18.3)4-153 | 1 | 22.62 |
| Pred | 7 | >250 (>250->250) | 9 | >250 (>250->250) | 8 | >250 (>250->250) | 3 | >250 (>250->250)4-153 | 4 | >250 (194->250) |
| VCR | 7 | 12.50 (1.95-28.52) | 7 | 0.60 (0.24-1.18) | 7 | 18.36 (1.33-38.00) | 3 | 0.50 (0.14-9.15)4-153 | 4 | 20.19 (1.82-41.60) |
| ASP‡ | 6 | 1.45 (0.49-1.77) | 8 | 0.14 (0.01-0.59) | 5 | 1.36 (0.03-10.10) | 2 | >10.0 (>10.0->10.0)4-153 | 2 | 0.66 (0.51-0.80)4-153 |
For comparison with other subgroups and the total group of AML patients, please see Table 3.
Data on statistical comparisons are given in “Results.” Results are expressed as median LC50 values in μg/mL. In parentheses, the 25th-75th percentile (P25-P75) is given. n indicates the number of samples tested for that particular drug; Ara-C, cytarabine; DNR, daunorubicin; Dox, doxorubicin; Ida, idarubicin; VP16, etoposide; 6-TG, 6-thioguanine; Mitox, mitoxantrone; Amsa, amsacrine; CdA, 2-chlorodeoxyadenosine; Bus, busulfan; Ifos, 4-HOO-ifosfamide; Pred, prednisolone; VCR, vincristine; ASP, l-asparaginase.
L-ASP in IU/mL, not in μg/mL.
Ranges are given instead of the P25-75.